These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 31319975)

  • 1. Clinical implications of circulating cell-free DNA quantification and metabolic tumor burden in advanced non-small cell lung cancer.
    Hyun MH; Lee ES; Eo JS; Kim S; Kang EJ; Sung JS; Choi YJ; Park KH; Shin SW; Lee SY; Kim YH
    Lung Cancer; 2019 Aug; 134():158-166. PubMed ID: 31319975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC.
    Nygaard AD; Holdgaard PC; Spindler KL; Pallisgaard N; Jakobsen A
    Br J Cancer; 2014 Jan; 110(2):363-8. PubMed ID: 24231948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinib.
    Winther-Larsen A; Fledelius J; Sorensen BS; Meldgaard P
    Lung Cancer; 2016 Apr; 94():81-7. PubMed ID: 26973211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Koh YW; Lee SJ; Park SY
    Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Various Metabolic Parameters Derived From Baseline 18F-FDG PET/CT as Prognostic Markers in Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy.
    Sharma A; Mohan A; Bhalla AS; Sharma MC; Vishnubhatla S; Das CJ; Pandey AK; Sekhar Bal C; Patel CD; Sharma P; Agarwal KK; Kumar R
    Clin Nucl Med; 2018 Jan; 43(1):e8-e17. PubMed ID: 29112011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole Body Metabolic Tumor Volume and Total Lesion Glycolysis Predict Survival in Patients with Adrenocortical Carcinoma.
    Satoh K; Patel D; Dieckmann W; Nilubol N; Kebebew E
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S714-20. PubMed ID: 26282908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
    Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
    Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of the
    Goksel S; Cengiz A; Ozturk H; Yurekli Y
    J Cancer Res Ther; 2021; 17(4):925-930. PubMed ID: 34528543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of Metabolic Tumor Volume and Total Lesion Glycolysis to Predict Prognosis in Early-Stage Lung Cancer at Preoperative Staging.
    Karaman E; Goksel S; Tuluce K
    J Coll Physicians Surg Pak; 2022 Jun; 32(6):740-745. PubMed ID: 35686405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 17. Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on
    Jin F; Qu B; Fu Z; Zhang Y; Han A; Kong L; Yu J
    Clin Lung Cancer; 2018 Jan; 19(1):e101-e108. PubMed ID: 28690012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non-Small Cell Lung Cancer:
    Morbelli S; Alama A; Ferrarazzo G; Coco S; Genova C; Rijavec E; Bongioanni F; Biello F; Dal Bello MG; Barletta G; Massollo M; Vanni I; Piva R; Nieri A; Bauckneht M; Sambuceti G; Grossi F
    J Nucl Med; 2017 Nov; 58(11):1764-1769. PubMed ID: 28450567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis.
    Zheng W; Quan B; Gao G; Zhang P; Huang L
    Lab Med; 2023 Mar; 54(2):130-141. PubMed ID: 36106407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer.
    Pellegrino S; Fonti R; Mazziotti E; Piccin L; Mozzillo E; Damiano V; Matano E; De Placido S; Del Vecchio S
    Ann Nucl Med; 2019 Dec; 33(12):937-944. PubMed ID: 31612416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.